FDA DEVICE FACTS
NEVISENSE
SCIBASE AB
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Nevisense is indicated for use on cutaneous lesions with one or more clinical or historical characteristics of melanoma, when a dermatologist chooses to obtain additional information when considering biopsy. Nevisense should not be used on clinically obvious melanoma. The Nevisense result is one element of the overall clinical assessment. The output of Nevisense should be used in combination with clinical and historical signs of melanoma to obtain additional information prior to a decision to biopsy.
Nevisense is indicated only for use on:
• primary skin lesions with a diameter between 2 mm and 20 mm;
• lesions that are accessible by the Nevisense probe;
• lesions where the skin is intact (i.e., non-ulcerated or non-bleeding lesions);
• lesions that do not contain a scar or fibrosis consistent with previous trauma;
• lesions not located in areas of psoriasis, eczema, acute sunburn or similar skin conditions;
• lesions not in hair-covered areas;
• lesions which do not contain foreign matter;
• lesions not on special anatomic sites (i.e., not for use on acral skin, genitalia, eyes, mucosal areas).
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。